Remove 2040 Remove Compliance Remove Conditions Remove Programs
article thumbnail

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update

Cannabis Law Report

” The patent provides protection through 2040 and describes use of the Company’s investigational drug ANEB-001 to treat acute cannabinoid overdose. In August Anebulo formed the SAB to advise the Company on its clinical development programs and product pipeline. In October the Company announced the issuance of U.S. 19,985,645. .